Dr. Reddy’s Competition For Perrigo’s Omeprazole Delayed Six Months
This article was originally published in The Tan Sheet
Executive Summary
Private label leader Perrigo should have an additional six months without competition from Dr. Reddy's against the firm's top-selling OTC product, the proton pump inhibitor omeprazole